Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Ga-68-Αvβ3 IAC Positron Emission Tomography (PET/CT) for Diagnosis and Clinical Management in Angiogenic Breast Cancer Patients.

Trial Profile

Safety and Efficacy of Ga-68-Αvβ3 IAC Positron Emission Tomography (PET/CT) for Diagnosis and Clinical Management in Angiogenic Breast Cancer Patients.

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AIP-301 (Primary)
  • Indications Breast cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms Shiva; The SHIVA Study
  • Sponsors Advanced Imaging Projects

Most Recent Events

  • 16 May 2024 Planned End Date changed from 30 Aug 2024 to 30 Aug 2025.
  • 16 May 2024 Planned primary completion date changed from 30 Aug 2024 to 30 Aug 2025.
  • 16 May 2024 Planned initiation date changed from 30 Aug 2022 to 30 Aug 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top